Import Procedures - Considerations
The Task Force considered whether additional disclosure of information about import procedures will give the public a better understanding of FDA activities to protect the food and medical product supply. The Task Force considered whether disclosure of more information about imported products or importers would deter future attempts by companies and individuals to import violative products into the United States.
The Task Force also considered the risk of confusing the public by disclosing additional information about imported products, particularly about the status of products that are detained at the border. Detentions do not mean that FDA has made a final determination with respect to the status of the product. Based on additional information, it may be determined that the products are compliant and should be allowed onto the U.S. market. The Task Force considered the public interest in disclosing information about products that currently are not, and may never be, sold on the U.S. market.